Search results
Genzyme was an American biotechnology company based in Cambridge, Massachusetts. Since its acquisition in 2011, Genzyme (also known as Genzyme Transgenics Corp or GTC Biotherapeutics) has been a fully owned subsidiary of Sanofi. In 2010, Genzyme was the world's third-largest biotechnology company, employing more than 11,000 people around the world.
Feb 3, 2022 · Eleven years after Sanofi bought Genzyme for about $20.1 billion, the parent company said Thursday it will no longer call its specialty care unit Sanofi Genzyme ― just Sanofi, as part of a ...
Jun 26, 2024 · Discover how Sanofi, a global pharmaceutical company, is shaping healthcare in the US with innovative solutions and treatments.
Feb 3, 2022 · Eleven years after Sanofi bought Genzyme for about $20.1 billion, the parent company said Thursday it will no longer call its specialty care unit Sanofi Genzyme ― just Sanofi, as part of a ...
2 days ago · Sanofi ’s subsidiary Genzyme is suing Sarepta Therapeutics, alleging that by producing and marketing the Duchenne muscular dystrophy gene therapy Elevidys (delandistrogene moxeparvovec-rokl), the biotech is infringing on the pharma’s protected technologies.. Sanofi’s lawsuit claims that Elevidys violates two of its patents—dubbed the 542 and 721 patents—which are related to the ...
4 days ago · Genzyme said in the lawsuit, opens new tab, made public on Monday, that Sarepta mimics Genzyme's technology for modifying viruses used to deliver genes into human cells in gene-therapy treatments ...
Aug 6, 2015 · Nexviazyme, a new ERT for late-onset Pompe disease. Nexviazyme is administered as a monotherapy ERT every two weeks. The recommended dose is based on body weight (20 mg/kg for LOPD patients ≥30 kg or 40 mg/kg for LOPD patients <30 kg) and is administered incrementally via intravenous infusion.
3 days ago · Sanofi ( NASDAQ: SNY )-owned Genzyme has sued Sarepta Therapeutics ( NASDAQ: SRPT) accusing the latter's Duchenne muscular dystrophy therapy Elevidys of violating two of its patents. The patents ...
Feb 16, 2011 · Sanofi-Aventis brought an end to its protracted pursuit of Genzyme with an agreed $20.1bn cash takeover of the US biotech company, coupled with additional conditional payments over the next...
Aug 6, 2021 · On Aug. 6, the US Food and Drug Administration (FDA) granted accelerated marketing approval to avalglucosidase alfa (Nexviazyme) for the treatment of people 1 year of age and older living with late-onset Pompe disease. It is the second approved drug to treat Pompe disease.
